Alluvi, known as BI 4744, represents a notable breakthrough in weight management therapy. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates remarkable results in https://alluvi716846.bcbloggers.com/profile